Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
- Medicine, BiologyInternational journal of molecular sciences
JAK2-V617F, the most prevalent mutation in MPNs, has been shown to activate a number of integrins on mature myeloid cells, including granulocytes and erythrocytes, which increase adhesion and drive venous thrombosis in murine knock-in/out models.
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
- Biology, MedicineJournal for ImmunoTherapy of Cancer
Targeting MDSCs as a therapeutic approach in cancer therapy is examined, with a special focus on GB1275 preclinical studies laying the rationale for the phase 1/2 clinical study.
Myeloid Cell Mediated Ilmmune Suppression in Pancreatic Cancer
- Biology, MedicineCellular and molecular gastroenterology and hepatology
Thromboinflammation Model-on-A-Chip by Whole Blood Microfluidics on Fixed Human Endothelium
- Medicine, BiologyDiagnostics
A thromboinflammation model which uses straight channels, lined with fixed human umbilical vein endothelial cells, after treatment with tumour necrosis factor-alpha and offers the advantage of the use of fixed endothelium, whole blood, instead of isolated neutrophils, and a small amount of blood.
TIME Is a Great Healer—Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes
- Biology, MedicineCells
This review will focus on macrophages as well as the phenotypes they acquire with the tumor immune microenvironment (TIME) in triple-negative breast cancer (TNBC).
Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations
- Medicine, BiologyJournal of clinical medicine
The pathophysiological reasoning behind therapeutic CRP apheresis is explained and the broad span of indications in which its application could be beneficial with a focus on ischemic stroke is summarized as well as the results of this therapeutic approach after myocardial infarction are summarized.
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
- Biology, MedicineNature communications
This study identifies collagen and LAIR1 as potential markers for immunotherapy resistance and validates multiple promising therapeutic combinations.
15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one sensitizes rectal tumor cells to anti-PD1 treatment through agonism of CD11b
- Biology, MedicineImmunopharmacology and immunotoxicology
Activation of CD11b with 15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one (HESEO) enhanced the therapeutic efficacy of anti-PD1 treatment in the tumor model, providing proof of concept for a new combination strategy involving molecular agonism ofCD11b to bypass the limitations of current clinical strategies to overcome resistance to immunotherapies.
Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer
- BiologyFrontiers in Oncology
Findings suggest that positive allosteric modulation of CD11b reduces TAM density and reprograms them to enhance the adaptive immune response and is a novel therapeutic strategy against lung cancer.
LFA-1 Controls Th1 and Th17 Motility Behavior in the Inflamed Central Nervous System
- BiologyFront. Immunol.
The results show that LFA-1 plays a pivotal role in T cell Motility during EAE and suggest that interfering with the molecular mechanisms controlling T cell motility can help to reduce the pathogenic potential of autoreactive lymphocytes.